Fortress Biotech, Inc. 8-K

What Happened Fortress Biotech, Inc. (FBIO) held its 2026 Annual Meeting of stockholders on June 17, 2026 (virtual). Stockholders elected seven directors to serve until the 2027 annual meeting and ratified KPMG LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2026. Total votes cast in the director elections were 12,897,124; broker non‑votes accounted for 1,602,838 of that total.

Key Details

• Meeting date: June 17, 2026; Form 8-K filed June 23, 2026.
• Directors elected (votes For / Against / Abstain / Total votes cast = 12,897,124):
  • Lindsay A. Rosenwald, M.D.: 11,022,326 For / 239,772 Against / 32,188 Abstain
  • Jimmie Harvey, Jr., M.D.: 10,322,230 For / 923,184 Against / 48,872 Abstain
  • Malcolm Hoenlein: 10,309,261 For / 932,328 Against / 52,697 Abstain
  • Dov Klein, CPA: 10,323,030 For / 931,434 Against / 39,822 Abstain
  • J. Jay Lobell: 9,756,949 For / 1,313,658 Against / 223,679 Abstain
  • Kevin L. Lorenz, J.D.: 10,131,410 For / 939,137 Against / 223,739 Abstain
  • Michael S. Weiss: 10,961,271 For / 270,249 Against / 62,766 Abstain
• Auditor ratification (KPMG LLP): 23,095,864 For / 753,612 Against / 341,934 Abstain.

Why It Matters

• Board composition: The re-election of seven directors determines the company’s board that will oversee strategy and governance through the next year; vote totals show varying levels of shareholder support across directors.
• Auditor confirmation: Ratifying KPMG LLP secures the company’s independent accounting firm for 2026, an important step for audit continuity and upcoming financial reporting.
• Investor takeaway: These are governance outcomes (not financial results) but are material to shareholders because they shape oversight and may influence future reporting and corporate decisions.